Vertex Pharmaceuticals IncorporatedCambridge, MA United States
Company Description
Vertex Pharmaceuticals aims to cure patients with previously incurable diseases. The biotechnology company uses an integrated, multidisciplinary approach -- employing biophysics, computer-based modeling, and functional genomics -- to speed up the discovery and development of new drugs. Its first commercial product, Incivek (telaprevir) for hepatitis C virus (HCV), was launched in 2011, and a second drug for cystic fibrosis, Kalydeco, was launched in 2012. The company has other drugs in development, including additional treatments for HCV and cystic fibrosis, as well as epilepsy and rheumatoid arthritis.
| 130 Waverly St. | Phone: 617-444-6100 | http://www.vpharm.com |
| Cambridge, MA 02139 | Fax: 617-444-6680 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Vertex Pharmaceuticals Incorporated Rankings
| S&P 400 |
Executives
| 102 executives listed for Vertex Pharmaceuticals Incorporated's Cambridge, MA location. | ||
| Chairman, President, and CEO | Matthew Emmens | |
|---|---|---|
| EVP and CFO | Ian Smith | |
| EVP and Chief Commercial Officer | NancyWysenski | |
Financials
| Company Type | Public - NASDAQ: VRTX Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 2,000 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Vertex Pharmaceuticals Incorporated now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
